Inito raises $29 Mn in Series B round led by Bertelsmann India

At-home diagnostics startup Inito has raised $29 million in a Series B round led by Bertelsmann India Investments, with participation from existing investor Fireside Ventures. 

The company’s total equity funding now stands at $45 million. It previously raised $6 million in a Series A round led by Fireside Ventures in November 2023.

The new capital will support Inito’s move beyond fertility testing into broader hormone and health diagnostics built on AI-enabled antibody engineering.

Inito entered the market in 2021 with an at-home fertility device that measures four hormone markers and interprets results using proprietary models. According to the company, the product has processed more than 30 million data points globally. After reaching scale in fertility monitoring, the company is developing tests for additional biomarkers across women’s and general health.

Co-founders Aayush Rai and Varun AV said the next phase of the business focuses on using computational protein design to build synthetic antibodies. This approach replaces conventional antibody development, which relies on animal-derived material and manual screening. 

Inito aims to create a stable, consistent foundation for at-home diagnostic tests that historically required clinical infrastructure.

The brand is building products for testosterone, thyroid, vitamins and other analytes, targeting a wider health-monitoring use case. Inito has teams across Bengaluru, Dubai and London and holds more than 20 patents linked to its testing platform.